Melatonin and Human Cardiovascular Disease
Journal of Cardiovascular Pharmacology and Therapeutics · 2017-03 · 22 (2) · 122-132
DOI: 10.1177/1074248416660622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 27.07.2016. Verfasst von Seithikurippu R Pandi-Perumal und 8 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Medicine, College of Medicine, The University Sleep Disorders Center, King Saud University, Riyadh, Saudi Arabia. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension, and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1 Department of Medicine, College of Medicine, The University Sleep Disorders Center, King Saud University, Riyadh, Saudi Arabia.
- 2 Division of Health and Behavior, Department of Population Health, New York University Medical Center, Center for Healthful Behavior Change, New York, NY, USA.
- 3 Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, USA.
- 4 CUNY School of Public Health at Brooklyn College, New York, NY, USA.
- 5 Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada.
- 6 Sleep Disorders Center, Ajax, Ontario, Canada.
Zitieren
APA
Pandi-Perumal, S. R., BaHammam, A. S., Ojike, N. I., Akinseye, O. A., Kendzerska, T., Buttoo, K., Dhandapany, P. S., Brown, G. M., & Cardinali, D. P. (2017). Melatonin and Human Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 22(2), 122-132. https://doi.org/10.1177/1074248416660622
Vancouver
Pandi-Perumal SR, BaHammam AS, Ojike NI, Akinseye OA, Kendzerska T, Buttoo K, et al. Melatonin and Human Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(2):122-132. doi:10.1177/1074248416660622
BibTeX
@article{PandiPerumal2017,
author = {Pandi-Perumal, Seithikurippu R and BaHammam, Ahmed S and Ojike, Nwakile I and Akinseye, Oluwaseun A and Kendzerska, Tetyana and Buttoo, Kenneth and Dhandapany, Perundurai S and Brown, Gregory M and Cardinali, Daniel P},
title = {Melatonin and Human Cardiovascular Disease},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2017},
volume = {22},
number = {2},
pages = {122--132},
doi = {10.1177/1074248416660622}
}
EUVIMED